RecruitingNCT07050550Updated Jul 3, 2025

A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury

An observational study in Liver Injury, sponsored by First Affiliated Hospital of Zhejiang University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-07-03.

Sponsored by First Affiliated Hospital of Zhejiang University · Observational

From the registry’s dates

Primary completion was expected by Aug 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
Started Dec 2024; still recruiting 1 year 10 months later.

Study type: Observational
Model: Cohort
Time perspective: Prospective
Enrollment: 45
Ages: 18 Years to 80 Years
Sex: All

Study summary

This study is a prospective exploratory clinical study aimed at evaluating the efficacy (sensitivity, specificity) of 18F-DFA PET imaging in assessing liver function damage. Subjects who meet the inclusion criteria are screened and enter this study to receive 18F-DFA PET imaging assessment, with clinical biochemical liver function indicators or liver puncture pathological examination as controls.

Read the detailed description

Liver injury (LI) refers to a clinical syndrome caused by a rapid decline in liver function due to various causes in a short period of time, manifested by increased transaminase and bilirubin, pain in the liver area, abdominal distension, and jaundice. Acute treatment should be systematically carried out because liver injury can lead to liver dysfunction and even liver failure, and severe liver necrosis, which is life-threatening.

Currently, peripheral blood biochemistry, ultrasound, CT, MR, and liver biopsy are routinely used in clinical practice to evaluate the physiological and pathological changes of the liver during liver injury. The assessment of liver function from plasma is indirect, and marker molecules such as transaminases are diluted in the entire blood volume. During liver failure, when various processes such as inflammatory storms occur simultaneously, the results will be disturbed. Among the above methods, liver biopsy is the gold standard. However, liver biopsy only samples 1/50,000 to 1/100,000 of the liver, resulting in significant sampling errors. This heterogeneity of the liver is particularly significant when liver disease is heterogeneous, such as during liver injury and liver failure. Therefore, it is particularly important to find a non-invasive visualization that can display liver damage and liver failure in real time.

Vitamin C (VC), also known as L-ascorbic acid, is an essential water-soluble vitamin for the human body. As part of antioxidant and carbohydrate metabolism, VC participates in the circulation between liver cells and organs, mainly involving the hexuronic acid pathway, pentose phosphate cycle, glycolysis and gluconeogenesis. Glycogenolysis, as the main source of UDP-glucuronic acid, determines the rate of the hexuronic acid pathway leading to ascorbic acid synthesis. Glycogenolysis is regulated by oxidized and reduced glutathione. Therefore, glycogen, ascorbic acid and glutathione metabolism are interrelated, and the three together affect the antioxidant status of the liver. 6-Deoxy-6-[18F]fluoro-L-ascorbic acid (18F-DFA) is a radioactive tracer for positron emission tomography (PET) based on the structure of natural ascorbic acid (vitamin C). Recent literature reports show that 18F-DFA PET imaging can be used to evaluate liver damage and liver failure caused by acetaminophen. It can be seen that 18F-DFA PET molecular imaging is a promising diagnostic method for acute liver function injury, which may have higher sensitivity and specificity for the diagnosis of liver function injury and the evaluation of therapeutic efficacy.

In order to further observe the clinical diagnostic effect of this imaging method, we designed this prospective exploratory clinical study to further determine the effectiveness and safety of 18F-DFA PET imaging in evaluating liver function injury. Study purpose: To evaluate the efficacy (sensitivity, specificity) of 18F-DFA PET imaging in evaluating liver function injury with clinical biochemical liver function indicators or liver puncture pathological examination as control. To evaluate the correlation between liver uptake of 18F-DFA and liver function injury indicators (clinical biochemical liver function indicators or liver puncture pathological results).

Conditions studied

Liver Injury

Keywords

liver injury
pet-ct
18F-DFA

In context

Lead sponsor

First Affiliated Hospital of Zhejiang University is the lead sponsor of 255 studies on the registry; 139 are open to participants now.

Counted across the registry records on this site, refreshed daily.

Who can participate

Ages eligible: 18 Years to 80 Years
Sexes eligible: All
Accepts healthy volunteers: No
Sampling method: Non-probability sample

Study population

Clinical diagnosis of liver damage (combined with medical history and laboratory tests, manifested as changes in liver enzymes, abnormal bilirubin metabolism, dysfunction of substance synthesis and decreased biodegradation function, including indicators such as ALT, AST, ALP, GGT, albumin (Alb), TBil and DBil);
Clinical diagnosis of liver failure (liver failure is a severe liver damage caused by multiple factors, resulting in severe dysfunction or decompensation of its synthesis, detoxification, excretion and biotransformation functions, and a group of clinical syndromes with coagulation dysfunction, jaundice, hepatic encephalopathy, ascites as the main manifestations. Key points for the diagnosis of liver failure (a) Extreme fatigue, and severe gastrointestinal symptoms such as obvious anorexia, vomiting and abdominal distension; (b) Progressive deepening of jaundice (serum TBil ≥171μmol/L or daily increase ≥17.1μmol/L); (c) Bleeding tendency, plasma prothrombin activity (PTA≤40

Inclusion criteria

1) Aged between 18 and 80 years old; 2) Clinically diagnosed with liver damage (combined with medical history and laboratory tests, manifested as changes in liver enzymes, abnormal bilirubin metabolism, dysfunction of substance synthesis, and decreased biodegradation function, including indicators such as ALT, AST, ALP, GGT, albumin (Alb), TBil, and DBil); 3) Clinically diagnosed with liver failure (liver failure is a severe liver damage caused by multiple factors, resulting in severe dysfunction or decompensation of its synthesis, detoxification, excretion, and biotransformation functions, and a group of clinical syndromes with coagulation dysfunction, jaundice, hepatic encephalopathy, ascites, etc. as the main manifestations. Key points for the diagnosis of liver failure (a) Extreme fatigue, and severe gastrointestinal symptoms such as anorexia, vomiting, and abdominal distension; (b) Progressive deepening of jaundice (serum TBil ≥171μmol/L or daily increase ≥17.1μmol/L); (c) Bleeding tendency, plasma prothrombin activity (PTA≤40% or international normalized ratio (INR ≥ 1.5; (d) hepatic encephalopathy (grade II or above) or other complications.); 4) informed consent and able to accept follow-up, can understand and comply with the requirements of the study

Exclusion criteria

Exclusion Criteria:

1) Patients with serious primary diseases of the heart, brain, kidney and hematopoietic system (i.e. Weber heart function grade D; hemoglobin (Hb) \<10 g/dL, white blood cells (WBC) \<3×109/L, platelets (PLT) \<90×109/L; creatinine clearance (CrCl) \<40 mL/min); 2) Patients with mental disorders or primary affective disorders; 3) Patients who cannot understand, follow the study protocol or sign the informed consent form; 4) Patients with contraindications to PET imaging (including pregnant women, breastfeeding women, women of childbearing age who have plans to have children in the near future, etc.); 5) Patients with allergies to imaging agents; 6) Patients who cannot cooperate with PET scanning due to hypoglycemia, severe pain or tremor.

Study design

Observational model: Cohort
Time perspective: Prospective
Enrollment: 45 participants (estimated)
Target follow-up: 6 Months
Patient registry: Yes

Groups and cohorts

liver injury
liver injury

What researchers measure

Primary outcomes

Change from Baseline in the MAX%ID SUV in PET-CT imaging at 6 Months
Change from Baseline in the MAX%ID SUV in PET-CT imaging at 6 Months
Time frame: The scan takes 10 minutes. After the scan is completed, patients will wait in the examination room for 1 hour before returning.
To evaluate the correlation between liver uptake of 18F-DFA and liver function injury indicators (clinical biochemical liver function indicators or liver puncture pathological results).
To evaluate the correlation between liver uptake of 18F-DFA and liver function injury indicators (clinical biochemical liver function indicators or liver puncture pathological results).
Time frame: The scan takes 10 minutes. After the scan is completed, patients will wait in the examination room for 1 hour before returning.

Study locations

1 of 1 sites recruiting

The First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU)
Hangzhou, Zhejiang 310006, China
Recruiting

References and documents

Individual participant data

Plan to share: Yes — After the study is completed, we will compile all the data into an article and publish it, including the imaging and clinical data of all patients.

Supporting information: Study protocol, Sap, Csr

No publications or documents are linked to this record.

Updates

Tracking since Sep 25, 2026

No changes since tracking began. The registry record was last updated on Jul 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗

Registry details

Key details

Study ID: NCT07050550
Lead sponsor: First Affiliated Hospital of Zhejiang University
Collaborators: National Natural Science Foundation of China
Responsible party: Sponsor
First posted: Jul 3, 2025
Start date: Dec 1, 2024
Primary completion: Aug 31, 2025 (estimated)
Completion: Dec 31, 2025 (estimated)
Last update: Jul 3, 2025

Study contacts

QINGQING HU, DOCTOR

Contact

ivyhu@zju.edu.cn

+8617799853795

Xiaowei XU, DOCTOR

principal investigator · Zhejiang University

Oversight

Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No

View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

First Affiliated Hospital of Zhejiang University

Start the discussion